New HFMD Vaccine Distribution Agreement Reached for Region
A new agreement aims to bring an HFMD vaccine to Malaysia, Singapore, and Brunei for children under five.
Updated on Oct. 15, 2026 in Allergies
Live Poll
Should governments prioritize the approval and distribution of vaccines for common contagious childhood illnesses?
Duopharma Biotech has signed a five-year agreement to distribute the EnVAX-A71 vaccine for hand, foot, and mouth disease (HFMD) in Malaysia, Singapore, and Brunei. If regulatory approval is granted, this would provide the first available HFMD vaccine in Malaysia.
Why it matters
Hand, foot, and mouth disease most commonly affects children under five years old. This partnership aims to expand access to preventative care for the infection, which currently lacks an approved vaccine in the Malaysian market.
The distribution agreement establishes a five-year framework for the EnVAX-A71 monovalent vaccine targeting Enterovirus A71, a common cause of HFMD. Whether this inoculation will secure regulatory marketing approval across the three designated countries remains unresolved.
The players
Duopharma Biotech
A pharmaceutical company focused on expanding its preventive healthcare and vaccine portfolio.
Enimmune Corporation
A Taiwan-based manufacturer that produces the EnVAX-A71 vaccine.
The details
The EnVAX-A71 vaccine is a monovalent inoculation specifically engineered to target the Enterovirus A71 strain. Under the new agreement, Duopharma (M) Sdn Bhd is responsible for securing necessary regulatory marketing approvals and managing all local marketing efforts. Enimmune Corporation will provide support for the required Good Manufacturing Practice assessments to ensure the vaccine meets regional quality standards.
Timeline
October 15, 2026: Duopharma announced the distribution agreement.
Health Landscape
This agreement tracks with the global shift toward developing specialized vaccines for Enterovirus A71 to protect children under five. It marks a significant step in establishing a commercial pipeline for HFMD prevention in Southeast Asia.
Parents of children under five should stay informed as regulatory reviews for the vaccine progress in their respective regions. You should discuss the status of local preventive options for HFMD with your pediatrician.
The takeaway
HFMD is most common in children five and younger, making preventative strategies a priority for public health in affected regions. Keep track of local health advisories for information on vaccine availability and pediatric protection guidelines.
Further reading
For more information on managing immune responses and vaccine developments, visit Allergies.
Source note: This article includes information reported by The Edge Malaysia.
Live Poll
Should governments prioritize the approval and distribution of vaccines for common contagious childhood illnesses?
